Brokerages Set Collegium Pharmaceutical, Inc. (NASDAQ:COLL) PT at $43.60

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.60.

A number of analysts have weighed in on the stock. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler cut their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Friday, January 10th.

Collegium Pharmaceutical Stock Down 0.4 %

Shares of NASDAQ:COLL opened at $30.82 on Friday. The firm’s 50 day moving average price is $31.04 and its 200 day moving average price is $34.10. The stock has a market cap of $993.95 million, a price-to-earnings ratio of 13.28 and a beta of 0.82. Collegium Pharmaceutical has a fifty-two week low of $28.39 and a fifty-two week high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Insider Buying and Selling

In other news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares of the company’s stock, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Several institutional investors have recently made changes to their positions in the stock. Victory Capital Management Inc. boosted its position in Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after purchasing an additional 215,874 shares during the period. Emerald Advisers LLC grew its position in Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock worth $31,967,000 after purchasing an additional 177,129 shares during the last quarter. JPMorgan Chase & Co. grew its position in Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in Collegium Pharmaceutical by 24.9% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock worth $25,591,000 after purchasing an additional 131,835 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Collegium Pharmaceutical in the 3rd quarter worth about $4,693,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.